Array Biopharma, Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc

ARRY 8.660

+3.2%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: GregorioAllegri who wrote (319)	1/14/2017 12:09:18 PM
From: GregorioAllegri	Read Replies (1) of 321

There is also competition in BRAF positive melanoma from immunotherapy MABs, specifically the combination of OPDIVO + YERVOY from BMY. The PFS for this combination was 11.5 months, comparable to the BRAF+MEK inhibitors. There is a suspicion that the MABs have longer lasting effects. The BMY combination is also effective on non-BRAF melanoma. Immunotherapy drugs seem to also benefit from combination with MEK inhibitors and there are at least 4 of these around including the ARRY drug, and the drug that Astrazeneca has licensed from ARRY. ga

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next